Contingent assessment of the COVID-19 vaccine

被引:106
作者
Garcia, Leidy Y. [1 ]
Cerda, Arcadio A. [1 ]
机构
[1] Univ Talca, Fac Econ & Business, 1 Poniente, Talca 1141, Chile
关键词
COVID-19; SARS-CoV-2; Vaccine; Acceptance; Health economics; Contingent valuation; WILLINGNESS-TO-PAY; PREFERENCES; ADOLESCENT;
D O I
10.1016/j.vaccine.2020.06.068
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The COVID-19 pandemic has not only had a negative impact on people's health and life behavior, but also on economies around the world. At the same time, laboratories and institutions are working hard to obtain a COVID-19 vaccine, which we hope will be available soon. However, there has been no assessment of whether an individual and society value a vaccine monetarily, and what factors determine this value. Therefore, the objective of this research was to estimate the individual's willingness to pay (WTP) for a hypothetical COVID-19 vaccine and, at the same time, find the main factors that determine this valuation. For this, we used the contingent valuation approach, in its single and double-bounded dichotomous choice format, which was based on a hypothetical market for a vaccine. The sample used was obtained through an online survey of n = 566 individuals from Chile. The main results showed that the WTP depends on the preexistence of chronic disease (p <= 0.05), knowledge of COVID-19 (p <= 0.05), being sick with COVID-19 (p <= 0.05), perception of government performance (p <= 0.01), employment status (p <= 0.01), income (p <= 0.01), health care (p <= 0.05), adaptation to quarantine with children at home (p < 0.01) and whether the person has recovered from COVID-19 (p < 0.10). According to our discrete choice model in double-bounded dichotomous format, it was concluded that the individuals' WTP is US$184.72 (CI: 165.52-203.92; p < 0.01). This implies a social valuation of approximately US$2232 million, corresponding to 1.09% of the GNP per capita. (C) 2020 The Author(s). Published by Elsevier Ltd.
引用
收藏
页码:5424 / 5429
页数:6
相关论文
共 24 条
[1]   Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: A global health emergency [J].
Acter, Thamina ;
Uddin, Nizam ;
Das, Jagotamoy ;
Akhter, Afroza ;
Choudhury, Tasrina Rabia ;
Kim, Sunghwan .
SCIENCE OF THE TOTAL ENVIRONMENT, 2020, 730
[2]  
[Anonymous], 2018, OECD Economic Surveys: Chile 2018, DOI [10.1787/ecosurveys-chl-2018, DOI 10.1787/ECOSURVEYS-CHL-2018]
[3]  
Boyle KJ, 2017, ECON NON-MARK GOOD, V13, P83, DOI 10.1007/978-94-007-7104-8_4
[4]   Phase 0/microdosing approaches: time for mainstream application in drug development? [J].
Burt, Tal ;
Young, Graeme ;
Lee, Wooin ;
Kusuhara, Hiroyuki ;
Langer, Oliver ;
Rowland, Malcolm ;
Sugiyama, Yuichi .
NATURE REVIEWS DRUG DISCOVERY, 2020, 19 (11) :801-818
[5]  
Cerda AA, 2014, SALUD PUBLICA MEXICO, V56, P48
[6]  
Cuccia T, 2020, HDB CULTURAL EC
[7]   Error by omitted variables in regret-based choice models: formal and empirical comparison with utility-based models using orthogonal design data [J].
Jang, Sunghoon ;
Rasouli, Soora ;
Timmermans, Harry .
TRANSPORTMETRICA A-TRANSPORT SCIENCE, 2020, 16 (03) :892-909
[8]   Covid-19: risk factors for severe disease and death [J].
Jordan, Rachel E. ;
Adab, Peymane ;
Cheng, K. K. .
BMJ-BRITISH MEDICAL JOURNAL, 2020, 368
[9]   Scope and magnitude of private sector financing and provision of immunization in Benin, Malawi and Georgia [J].
Levin, Ann ;
Munthali, Spy ;
Vodungbo, Venance ;
Rukhadze, Natia ;
Maitra, Kuhu ;
Ashagari, Tesfaye ;
Brenzel, Logan .
VACCINE, 2019, 37 (27) :3568-3575
[10]  
Lopez-Feldman A., 2012, Introduction to contingent valuation using Stata